Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Apr 24, 2024 — Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option.
U.S. Food and Drug Administration (FDA) Grants Full Approval for ... - News
NORTH CHICAGO, Ill., March 22, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary ...
FDA approves mirvetuximab soravtansine-gynx (Elahere, …
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 — ELAHERE ® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer; ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease ... - News
Jun 4, 2023 — ELAHERE demonstrated a statistically significant and clinically meaningful improvement in OS compared to IC chemotherapy.
FDA grants accelerated approval to mirvetuximab soravtansine …
On November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha...
ImmunoGen ELAHERE wins accelerated FDA approval for ovarian …
4 days ago — ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval.
Elahere secures full approval from FDA for types of ovarian cancer
Mar 25, 2024 — AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.
ELAHERE - Business Wire
Sep 28, 2023 — ELAHERE demonstrated clinically meaningful improvement in PFS and ORR by investigator assessment and in OS compared to IC chemotherapy, regardless of prior PARPi exposure.
AbbVie’s New ‘Biological Missile’ Ovarian Cancer ... - Forbes
Mar 22, 2024 — The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen’s cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments ...
- Some results have been removed